Acute respiratory tract infections (ARTIs) are an important cause of morbidity and mortality among children under the age of 5 years \[[@R1],[@R2]\], with the highest number of deaths occurring in developing countries \[[@R3]\]. In China, pneumonia is the leading cause of deaths in children under 5 years old with an estimated \>30 000 deaths annually \[[@R4]\]. Viruses have been considered as the most frequent causes of ARTIs. The predominant viruses associated with ARTIs in children include respiratory syncytial virus (RSV), influenza virus (IV), parainfluenza virus (PIV), human rhinovirus (HRV) and adenovirus (ADV) \[[@R5],[@R6]\].

RSV is the leading cause of ARTIs in early childhood. It is estimated that 33.8 million new episodes of RSV--associated ALRI occurred worldwide in children younger than 5 years, with at least 3.4 million episodes representing severe RSV--associated acute lower respiratory infection (ALRI) necessitating hospital admission \[[@R7]\]. The pattern of RSV infections is variable and related to season, socio--demographic and characteristics of study populations.

China has the largest child population and has substantial differences in climate from region to region. It has a variety of temperature and rainfall zones, including continental monsoon areas. The total population of children aged 14 years or younger is estimated to be 230 million. Although the epidemiology of RSV infections has been studied in cities such as Beijing, Chongqing and Lanzhou \[[@R8]--[@R10]\], few RSV studies in China have been published in English. Therefore, we performed a systematic review and meta--analysis of published studies to evaluate the epidemiology of RSV infections in patients with ARTIs.

A better understanding of the epidemiology of RSV infections plays a key role for the prevention, control and treatment of ARTIs. The objective of this systematic review and meta--analysis was to evaluate the etiology, serotypes, clinical features, age distribution and seasonality associated with RSV infections in China.

METHODS
=======

Search strategy
---------------

A systematic search was performed in indexed databases, including Chinese BioMedical Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang database and PubMed to identify available RSV studies in China. The following search terms were used: RSV or syncytial virus. Taking into account the quality of studies, high quality publications from the Chinese core journals (2014 edition) \[[@R11]\] were considered in the final analysis. The Library of Perking University evaluates all Chinese journals every four years and excludes lower quality journals using the quality measurement similar to the impact factors. To obtain recent data, the search strategy was limited to publications dated from January 2010 to Mar 2015. Details of the search strategy are presented in Appendix S1 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**.

Inclusion and exclusion criteria
--------------------------------

To be included, the following criteria had to be fulfilled: 1) studies in humans; 2) studies in patients with ARTIs; 3) studies that had at least one following outcome: etiology of acute respiratory infections; seasonality; gender; age group; serotypes; clinical features; 4) studies published in Chinese or English.

Publications were excluded if they were: 1) animal experiments or basic research (examples, studies focus on principles or mechanisms using cells and tissues); 2) case reports, systematic review or meta--analysis; 3) replicates (when the same population was studied in more than one publication, only the latest one or the one with the most complete data was considered for the meta--analysis).

ARTIs was defined as patients who were present of one or more respiratory symptoms, including watery eyes, rhinorrhea, nasal congestion or sinus congestion, otitis media, pharyngitis, cough, sore throat, sneezing, headache, and muscle pain. Meanwhile, patients had at least one symptom during acute infection, with high fever (body temperature ≥38°C) or chillness or normal/low leukocyte count or who were diagnosed with pneumonia by chest radiography previously. Chest radiography was conducted according to the clinical situation of the patient, and pneumonia was defined as an acute illness with radiographic pulmonary shadowing (at least segmental or in one lobe) by chest radiography.

Literature screening and data extraction
----------------------------------------

Literature reviewers were divided into two parallel groups. Using the set criteria of inclusion and exclusion, the reviewers independently screened the literature by title, keyword and abstract. Any disagreement was solved by a third reviewer. If they were not sure whether the study should be included, the decision was made based on further review of the full texts. NoteExpress 2 (Aegean Software Corporation, Shanghai, China) was used for the bibliography management.

Two parallel groups independently extracted the following data from eligible studies: general information, methodological quality and outcome data. Inconsistencies between two groups were checked after data extraction. Any disagreements were solved by the third reviewer.

Quality assessment
------------------

This meta--analysis included various types of studies with different outcomes. Therefore, no pre--existing scale is directly suitable for the assessment. The 5--item specific rating scale was developed to assess the quality of studies. These included 1) Did the study report patients' information? 2) Did the study report diagnosis criteria of acute respiratory infection? 3) Did the study report specimen collection methods? 4) Did the study report pathogen detection methods? 5) Did the study report statistical methods? Each item was scored on three scales; 0 indicating low quality, 1 indicating medium quality, and 2 indicating high quality. The score for each item was then added to give a composite score for the study, with a highest total score of 10. If the total score was equal to or greater than 8, we regarded the study as "good" quality.

Statistical analysis
--------------------

The MetaAnalyst (Beta 3.13; Tufts Evidence--based Practice Center, Boston, USA) was used to conduct meta--analyses for pooled proportions and odds ratios. Considering heterogeneity across all studies, we chose a random--effects model to carry out meta--analysis using Der--Simonian Laird method. The publication bias was determined via Stata 12.0 (StataCorp LP, Texas, USA) using an Egger's test. Meta--analysis for combining the results of studies was weighted to provide the balanced results of all included studies.

RESULTS
=======

Selection of studies
--------------------

Of the total of 4852 studies identified through the databases, 135 studies were included in the analysis ([**Figure 1**](#F1){ref-type="fig"}). Of the 135 studies, 123 studies were in children less than 16 years old and the remaining studies were in both children and adults. Of the 135 studies, 19 studies were published in English. The detailed information about author, publication year, province, age, specimen type, detection methodology, number of specimen and study outcomes are listed in Appendix S2 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**.

![Flow diagram of literature search and selection. \*Including: 1) Did not discuss respiratory tract infections or respiratory syncytial virus; or 2) only as background to discuss; or 3) used the abbreviation "RSV", but not referring to respiratory syncytial virus. †These studies reported/included charts or risk ratios and the numerators and denominators were not available.](jogh-05-020417-F1){#F1}

For the 135 studies, the quality evaluation score ranged from 5 to 10 points, with a mean ± standard deviation of 7.7 ± 1.3. There were 80 studies with a score of [≥]{.ul}8. The summary of quality assessment is listed in Appendix S3 in **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**.

Etiology
--------

The overall positivity rate of RSV among patients with ARTIs was 18.7% (95% CI 17.1--20.5%), followed by HRV, human bocavirus (HBoV), IV, PIV, human metapneumovirus (HMPV), enterovirus, ADV and human coronavirus (HCoV). ([**Table 1**](#T1){ref-type="table"}).

###### 

Etiology of acute respiratory infection in all ages

  Virus         No. articles included   Virus--positive   Total patients   Positive rate (%, 95% CI)
  ------------- ----------------------- ----------------- ---------------- ---------------------------
  RSV           132                     81 747            489 641          18.7 (17.1--20.5)
  Rhinovirus    36                      3647              31 605           11.5 (9.8--13.5)
  HBoV          45                      5899              110 345          6.8 (5.5--8.5)
  IV            95                      17 115            262 089          6.5 (5.4--7.7)
  PIV           97                      17 515            264 538          6.4 (5.6--7.2)
  HMPV          59                      5935              130 620          4.3 (3.6--5.1)
  Enterovirus   16                      923               17 689           4.0 (2.8--5.6)
  Adenovirus    96                      9618              275 380          3.4 (2.9--3.9)
  HCoV          39                      1544              66 048           2.6 (2.0--3.4)

RSV -- respiratory syncytial virus, PIV -- parainfluenza virus, IV -- influenza virus, HMPV -- human metapneumovirus, HBoV -- human bocavirus; HCoV, Human coronavirus, CI -- confidence interval

The prevalence of RSV was stratified into inpatients, outpatients, inpatients/outpatients and unknown category. RSV was found most frequently among inpatients 22.0% (95% CI 19.9--24.2%), followed by inpatients/outpatients, outpatients and unknown ([**Table 2**](#T2){ref-type="table"}).

###### 

Positive rate of RSV infection in acute respiratory tract infected patients

                                       No. articles included   Virus--positive   Total patients   Positive rate (%, 95% CI)
  ------------------------------------ ----------------------- ----------------- ---------------- ---------------------------
  **Settings:**                                                                                   
  Inpatient                            86                      67 319            366 386          22.0 (19.9--24.2)
  Outpatient                           9                       1061              9229             14.0 (9.6--19.9)
  Inpatient/outpatient                 45                      8779              67 826           15.8 (12.1--20.2)
  Unspecified                          95                      4568              46 200           11.4 (7.4--17.1)
  Total                                132                     81 747            489 641          18.7 (17.1--20.5)
  **Age groups:**                                                                                 
  0--6m                                45                      12 522            43 222           29.9 (26.2--33.8)
  0--1y                                65                      29 607            113 386          26.5 (23.7--29.5)
  0--3y                                55                      27 544            130 152          23.7 (20.9--26.9)
  0--6y                                47                      17 854            121 717          19.5 (16.0--19.6)
  0--16y                               72                      57 193            351 426          17.7 (5.5--8.5)
  ≥16y                                 7                       440               18 781           2.8 (1.3--6.1)
  **Inpatients only by age groups:**                                                              
  0--6m                                31                      10 690            35 592           32.4 (27.7--37.4)
  0--1y                                44                      25 259            97 542           34.4 (28.9--40.4)
  0--3y                                37                      20 789            99 951           24.3 (20.6--28.3)
  0--6y                                28                      12 446            88 248           19.8 (16.4--23.7)
  0--16y                               45                      46 128            270 359          20.0 (17.9--22.3)
  ≥16y                                 3                       174               8604             2.8 (0.8--9.8)
  **Regions:**                                                                                    
  Northeast                            2                       285               3003             9.5 (8.5--10.6)
  North China                          18                      2203              26 710           10.9 (6.3--18.4)
  South China                          23                      10 625            96 413           15.7 (13.2--18.6)
  East China                           44                      50 001            273 312          17.6 (15.3--20.2)
  Central China                        14                      2978              16 346           22.5 (16.8--29.5)
  Northwest                            9                       1523              5010             27.6 (21.3--34.9)
  Southwest                            20                      10 375            35 970           28.7 (25.7--32.0)
  Multi--regions                       2                       3757              32 877           14.7 (6.6--29.6)
  **Detection methodology**\*                                                                     
  IF                                   51                      41 201            230 033          17.0 (14.4--20.0)
  PCR                                  73                      32 814            201 063          19.9 (17.9--22.1)
  Others                               8                       7732              58 545           20.1 (15.8--25.3)

\*PCR -- polymerase chain reaction, IF -- immunofluorescence, Others -- refers to PCR/IF and RVP Fast, y -- year, m -- month, CI -- confidence interval

Seasonal characteristics
------------------------

A total of 45 studies reported the seasonality of RSV infections. Of these 45 studies, 28 studies reported monthly isolation rates and the remaining 17 studies reported quarterly. The peak of RSV infections mainly occurred in winter and spring ([**Table 3**](#T3){ref-type="table"}).

###### 

Seasonal epidemic characteristics of RSV infection among acute respiratory infected patients

  Month/season\*   No. articles included   RSV--positive   Total patients   Positive rate (%) (95% confidence interval)
  ---------------- ----------------------- --------------- ---------------- ---------------------------------------------
  Jan              17                      1150            4672             24.7 (15.2--37.5)
  Feb              17                      1094            4311             25.1 (17.1--35.4)
  Mar              17                      849             4003             19.5 (13.5--27.4)
  Apr              16                      504             3174             17.4 (13.5--22.3)
  May              15                      181             2551             8.7 (6.1--12.3)
  Jun              14                      135             2945             5.5 (3.1--9.4)
  Jul              14                      105             2805             4.5 (3.--6.8)
  Aug              13                      163             2605             7.0 (4.5--10.7)
  Sep              14                      183             2511             6.4 (3.6--11.3)
  Oct              16                      254             2935             7.5 (4.2--13.1)
  Nov              17                      597             3522             14.4 (8.8--22.5)
  Dec              17                      1049            3954             26.2 (17.9--36.8)
  Spring           27                      5627            37 738           13.9 (11.1--17.4)
  Summer           27                      2008            31 716           5.3 (3.7--7.6)
  Autumn           27                      4204            28 223           11.8 (8.2--16.8)
  Winter           27                      9774            32 937           22.7 (17.4--29.1)

\*Spring -- 1 March to 31 May, Summer -- 1 June to 31 August, Autumn -- 1 September to 30 November, Winter -- 1 December to 28/29 February.

Gender characteristics
----------------------

A total of 36 studies reported gender characteristics of RSV infections. Among 96 694 male patients, RSV was positive in 17 163 patients (20.4%, 95% CI 16.6--24.8%). Among 54 958 female patients, RSV was positive in 8364 (19.9%, 95% CI 16.0--24.4%).

RSV serotypes
-------------

There were 23 studies that reported RSV serotypes. Among 4172 RSV infected patients; type A, type B and mixed type A and B were detected in 2469 (63.1%, 95% CI 52.3--72.8%), 1611 (35.6%, 95% CI --6.0 to --46.6%) and 92 (1.2%, 95% CI 0.7--2.2%), respectively.

Clinical characteristics
------------------------

Twenty--five studies reported the clinical manifestations of RSV infection. The most frequently reported clinical manifestations were cough, sputum production, wheezing and fever ([**Table 4**](#T4){ref-type="table"}).

###### 

Clinical characteristics of RSV related acute respiratory infected patients

  Clinical characteristics   No. articles included   Symptomatic patients   RSV infected patients   Percent (95% CI)
  -------------------------- ----------------------- ---------------------- ----------------------- -------------------
  Cough                      24                      9880                   11 194                  93.9 (91.0--96.0)
  Expectoration              6                       1578                   2316                    66.3 (43.8--83.2)
  Wheeze                     13                      1768                   2778                    65.7 (56.5--73.8)
  Fever                      22                      3738                   10 018                  43.0 (37.5--48.7)
  Rhinorrhea                 8                       1621                   5669                    42.7 (31.6--54.6)
  Cyanosis                   9                       1346                   4318                    38.9 (15.8--68.2)
  Tachypnea                  11                      2024                   7737                    32.2 (15.7--54.9)
  Diarrhea                   7                       838                    5272                    18.8 (11.4--29.5)
  Dyspnoea                   8                       1707                   7918                    12.8 (5.0--28.9)

Sensitivity analysis and publication bias
-----------------------------------------

The conclusions remained robust and the outcomes did not alter significantly when only 'good' quality studies were evaluated in the sensitivity analysis. The overall RSV positivity rates were 19.7% (95% CI 17.7--21.9%) in all patients (n = 79), 22.7% (95% CI 20.2--25.3%) in inpatients (n = 53), and 13.8% (95% CI 8.3--22.0%) in outpatients (n = 5).

Publication bias was tested using the Egger's test. No publication bias was detected when verifying the 132 publications that reported RSV positive rates in all patients (--0.27, 95% CI --1.19 to --0.65, *P* = 0.563).

DISCUSSION
==========

RSV is the most common viral cause of ARTIs in developed and developing countries \[[@R7],[@R12]\]. However, the available epidemiological data on RSV in China has not been systematically summarized in English. Our results highlight that RSV is the leading cause of viral ARTIs in China.

The burden of respiratory viral infections is difficult to measure and is likely to differ from country to country due to several factors such as socio--demographic distribution, seasonal variation, study design and diagnostic techniques. In our study, RSV was the most frequently detected pathogen among patients with ARTIs in all age groups studied. Consistent with other studies, RSV and HRV were the most prevalent viruses in children \[[@R2],[@R13],[@R14]\].

In the present study, only 12 studies reported the RSV infections in adult patients and the remaining 123 studies were in children. Infants aged ≤1 year were at higher risk of RSV associated ARTIs, compared with those in other age groups. This is consistent with the previous reports of RSV in both developed and developing countries \[[@R7],[@R12],[@R15],[@R16]\]. The data show that RSV accounted for nearly 30% of all ARTIs in infants. Efforts to prevent RSV infections in infants can lead to a substantial reduction of RSV associated morbidity, mortality and medical costs in China. Further evidence of RSV disease burden can be established by adding RSV studies in existing influenza surveillance systems.

The relation between RSV infections and climate has been well documented \[[@R17],[@R18]\]. In regions with persistently warm temperatures and high humidity, RSV activity is continuous throughout the year, peaking in summer and early autumn. In temperate climates, RSV activity is maximal during winter, correlating with lower temperatures. In areas where temperatures remain colder throughout the year, RSV activity also occurs almost continuously \[[@R17],[@R18]\]. Most areas of China have a temperate climate. We found that the peak of RSV activity mainly occurred during winter and spring in China, which is similar to the previous reports \[[@R19]--[@R21]\]. This pattern of seasonality corresponds to the cold and dry seasons. However, we are unable to report regional differences in RSV activity due to limited data availability.

Based on genetic and antigenic variations in structural proteins, RSV isolates are subdivided into two major antigenic types (A and B). Both types are associated with mild to severe ARTIs \[[@R22]--[@R24]\]. Studies have shown that type A and B viruses co--circulate in the same area during epidemic periods and have various patterns of predominance \[[@R25]--[@R28]\]. However, the prevalence of each type may shift yearly and can vary among different communities \[[@R28]--[@R30]\]. Our analysis showed that type A was the predominant serotype accounting for 63.1% of all RSV infections. However, it is difficult to know how the sero--epidemiological trend changed in the recent years in China. This is because the study periods and locations varied substantially among included studies.

The studies we included differed in their methods of sampling and case--definition. Therefore, caution should be taken when interpreting the results. In our study, only 42 studies presented detailed criteria for case--definition. In addition, only 54 out of the 135 included studies used immunofluorescence for RSV detection. RSV was identified less frequently (17.0%) if only the results of studies based on immunofluorescent detection were included. In comparison with immunofluorescence, molecular diagnostics are more sensitive and specific \[[@R31],[@R32]\]. In recent years, the introduction of nucleic acid based diagnostic tests has markedly improved our understanding of viral etiology among ARTI patients \[[@R33]\]. Therefore, the real burden of RSV in China is likely to be higher than our findings if more sensitive diagnostic methods are used.

These differences in case definitions and diagnostic techniques are likely to have impacted the results. Therefore, a random effects model was applied to take into account the heterogeneity between studies resulting in wider 95% CIs with more conservative estimates of the overall results \[[@R34]\]. In addition, the etiology data in the present study should be interpreted with caution. This is because restricting RSV to the title and abstract in the search criteria is a potential source of bias and might not be representative of all studies reporting other viruses. However, all included studies in current review tested for multiple viruses. Therefore, it is reasonable to assume that the use of correct denominator and numerators allow us to present the useful and informative etiology data available in these studies.

In conclusion, this systematic review and meta--analysis showed that RSV is the leading cause of ARTIs in China, particularly among infants. Our findings are valuable for guiding the selection of appropriate therapies for ARTIs and implementation of preventive measures against RSV infections. Despite the disease burden, no effective RSV vaccine is currently available. Our data further supports the development of a successful RSV vaccine as a high priority.
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